INVESTIGATION OF THE APOPTOTIC EFFECT OF 147-DENA MONOCLONAL ANTIBODY IN BREAST CANCER TREATMENT
Project no. 20885 · Status: Kapanmış (Yayın bekleniyor) · 2019
Summary
Breast cancer is the type of cancer that most commonly affects women worldwide. In the treatment of breast cancer, which is very heterogeneous molecularly, it is of great importance to develop personalized and targeted treatment methods. Deaminoneuraminic acid (KDN) is a member of the sialic acid family and its expression level is negligibly minimal in normal human tissues, while there is a significant increase in cancer cells. Its increased expression in tumor tissues has characterized this molecule as an “oncodevelopmental antigen”. A monoclonal antibody against the KDN antigen has been produced by our research group: 14-DENA. In this study, it is aimed for 14-DENA; i) to determine the cytotoxic dose on two molecularly different breast cancers, ii) to examine the effects of the determined dose on apoptosis, which is one of the cell death mechanisms, iii) to examine the expression of apoptotic markers by immunofluorescence method, iv) to analyze cell morphology changes induced by apoptosis by Scanning Electron Microscopy and v) to analyze gene expression profiles. The results showed that 14-DENA had a cytotoxic effect on breast cancer cells and not on breast epithelial cells. Cytotoxicity was caused through induction of the apoptosis pathway. Apoptotic proteins that play a central role in this pathway showed increased expression and a decrease in anti-apoptotic protein expressions was observed. Apoptotic morphological changes occurred in these cells. It has been found that there are regulatory changes in gene expressions that are effective in cell metabolism and apoptosis.